| Not Yet Recruiting | Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures NCT07495657 | Assiut University | — |
| Not Yet Recruiting | Efficacy of Topical Metformin in Psoriasis Vulgaris NCT07516821 | Cairo University | N/A |
| Recruiting | Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLA NCT07426120 | Psoriasis Research Institute of Guangzhou | Phase 3 |
| Not Yet Recruiting | Topical Diacerein in Psoriasis Vulgaris NCT07352306 | Cairo University | Phase 4 |
| Recruiting | Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris NCT07320872 | Aswan University | — |
| Enrolling By Invitation | The Efficacy of Topical Formulation Containing Ciplukan (Physalis Angulata Linn.) on Psoriasis Vulgaris Lesion NCT06887322 | Universitas Padjadjaran | Phase 1 / Phase 2 |
| Recruiting | Proactive TDM Versus Standard Use of Biologics in Psoriasis NCT06398106 | University Hospital, Ghent | Phase 4 |
| Not Yet Recruiting | Topical Thymoquinone in Psoriasis Vulgaris NCT06508372 | Assiut University | N/A |
| Not Yet Recruiting | Botox Versus Tacrolimus in Psoriasis Vulgaris NCT06203470 | Assiut University | Phase 4 |
| Not Yet Recruiting | PSODEEP2 Pilot Study on Koebner Induction in Psoriasis NCT06414382 | Skane University Hospital | N/A |
| Unknown | Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis NCT05815797 | Chinese University of Hong Kong | Phase 2 |
| Completed | Impact of the Mediterranean Diet on Patients with Psoriasis NCT06257641 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | N/A |
| Completed | A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris NCT06191042 | selectION Therapeutics GmbH | Phase 1 |
| Recruiting | Correction of Psoriatic T Cell Signatures by Deucravacitinib NCT05858645 | University of California, San Francisco | Phase 4 |
| Completed | Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis NCT06042647 | Dermatology Consulting Services, PLLC | Phase 4 |
| Completed | The Mediterranean Diet and Time-Restricted Eating Dietary Interventions for Psoriasis Study NCT05820698 | King's College London | N/A |
| Completed | Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus NCT06475586 | University of Banja Luka | Phase 4 |
| Completed | Frequency of Tuberculosis in Psoriasis Patients NCT06563635 | Bezmialem Vakif University | — |
| Unknown | Hormonal Associations in Male Patients With Psoriasis Vulgaris NCT05716152 | Sohag University | — |
| Withdrawn | Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vul NCT03507946 | Ismart | N/A |
| Withdrawn | Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis NCT05499416 | Innovaderm Research Inc. | Phase 4 |
| Completed | Topical SGX302 for Mild-to-Moderate Psoriasis NCT05442190 | Soligenix | Phase 2 |
| Completed | Laser Induced Changes to Innervation and Vascularisation of Psoriatic Skin NCT05079256 | Nick van der Beek | N/A |
| Unknown | Using Acetylcysteine and Vitamin E With Psoriasis Vulgaris NCT05906498 | Badr University | Phase 3 |
| Unknown | Psoriatic Immune Response to Tildrakizumab NCT05390515 | University of California, San Francisco | Phase 4 |
| Unknown | Low-Salt Diet Effect on Th17-Mediated Inflammation and Vascular Reactivity in Psoriasis NCT05892640 | Josip Juraj Strossmayer University of Osijek | N/A |
| Unknown | Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients NCT05683015 | University Hospital, Ghent | Phase 4 |
| Completed | Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Pso NCT04306315 | LEO Pharma | Phase 4 |
| Completed | Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis NCT06011083 | Assiut University | N/A |
| Completed | Biofeedback for Psoriasis NCT05506644 | Bastyr University | N/A |
| Unknown | Impact of Non-surgical Periodontal Therapy in the Management of Plaque Psoriasis. NCT05311501 | University of Siena | N/A |
| Unknown | Augmenting Standard-of-care Treatment of Plaque Psoriasis by Neuromodulation NCT05243303 | Burrell College of Osteopathic Medicine | N/A |
| Completed | Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1% NCT05461456 | OrchestratePharma GmbH | Phase 1 |
| Active Not Recruiting | Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLA NCT05185258 | Aarhus University Hospital | Phase 4 |
| Completed | Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis NCT05102474 | University of California, San Francisco | — |
| Completed | Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, Ps NCT05215561 | Novartis Pharmaceuticals | — |
| Unknown | Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris NCT05254249 | Dr. Soetomo General Hospital | Phase 1 / Phase 2 |
| Unknown | ATG5 as a Serum Marker of Autophagy in Psoriatic Patient NCT05279638 | Sohag University | — |
| Completed | A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis NCT05120297 | Akeso | Phase 3 |
| Unknown | Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines NCT05144165 | Centre of Evidence of the French Society of Dermatology | — |
| Unknown | Pilot Study of Traditional Chinese Medicine (Qing-Re-Liang-Xue Decoction) as Complementary Medicine for Psoria NCT04994951 | The First Affiliated Hospital of Zhejiang Chinese Medical University | Phase 2 |
| Recruiting | Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis NCT04950218 | Herlev and Gentofte Hospital | — |
| Completed | Plexin B2 Gene Expression and Polymorphisms in Psoriasis NCT05184348 | South Valley University | Phase 1 |
| Unknown | Ultraviolet Radiation Forecasting Based Heliotherapy For Psoriasis in Bangkok, Thailand NCT04740983 | Chulalongkorn University | N/A |
| Unknown | The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders NCT04750161 | St. James's Hospital, Ireland | — |
| Withdrawn | Iontophoresis in Psoriasis NCT03979664 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Terminated | Dose Tapering Study of Adalimumab in Psoriasis NCT04028713 | University Hospital, Ghent | Phase 4 |
| Terminated | Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequa NCT04533737 | LEO Pharma | Phase 4 |
| Completed | Blue Light in the Treatment of Inflammatory Skin Diseases NCT06516783 | Medical University of Lodz | N/A |
| Completed | Modified Intermittent Fasting in Psoriasis NCT04418791 | University Hospital, Ghent | N/A |
| Completed | Predicting Inflammatory Skin Disease Response to IL-23 Blockade NCT04541329 | University of California, San Francisco | Phase 4 |
| Completed | Blue Light Phototherapy NCT04343586 | Northwestern University | N/A |
| Terminated | An Explorative Psoriasis Biomarker Study NCT04394936 | Centre for Human Drug Research, Netherlands | N/A |
| Completed | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis NCT04340076 | Radboud University Medical Center | Phase 4 |
| Unknown | Liver Fibrosis and Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate NCT04493762 | The University of Hong Kong | — |
| Unknown | Glucose Trnsporter and PEDF in Psoriasis NCT04242082 | Assiut University | — |
| Completed | Improvement of Psoriasis Patients' Adherence to Topical Drugs NCT04220554 | Odense University Hospital | N/A |
| Completed | Therapeutic Drug Monitoring of Ixekizumab in Psoriasis Patients NCT04083612 | University Hospital, Ghent | Phase 4 |
| Unknown | Therapeutic Drug Monitoring of Risankizumab in Psoriasis Patients (BIOLOPTIM-RIS) NCT05685940 | University Hospital, Ghent | Phase 4 |
| Withdrawn | A Pilot Study to Explore the Role of Gut Flora in Psoriasis NCT04099979 | ProgenaBiome | — |
| Completed | Effect Narrow-Band UVB Radiations NCT05647187 | South Valley University | N/A |
| Completed | Use of Alternative Therapy in Psoriasis Vulgaris Patients NCT04207216 | Istanbul Medeniyet University | — |
| Completed | Social Media Use of Psoriasis Vulgaris Patients: Multicenter, Survey Work NCT04207242 | Istanbul Medeniyet University | — |
| Completed | Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis NCT04472546 | Pierre Fabre Dermo Cosmetique | N/A |
| Completed | Impact of Decision-Framing in Psoriasis NCT04136314 | University of Southern California | N/A |
| Completed | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis) NCT03885089 | Pfizer | — |
| Completed | Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral NCT03816917 | Radboud University Medical Center | — |
| Unknown | Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome NCT03961230 | Shanghai Yueyang Integrated Medicine Hospital | Phase 2 |
| Unknown | Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Stasis Syndrome NCT03942198 | Shanghai Yueyang Integrated Medicine Hospital | Phase 2 |
| Completed | Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients NCT03807453 | Istanbul Medeniyet University | — |
| Completed | Metabolic Syndrome in Psoriasis and Psoriatic Arthritis and Correlation With Serum Omentin and Visfatin Levels NCT03932110 | Istanbul Medeniyet University | N/A |
| Completed | Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Di NCT03898583 | LEO Pharma | Phase 1 |
| Unknown | Combined Oral Vitamin D and UVB Versus UVB Alone in Treatment of Psoriasis Vulgaris NCT03874975 | Assiut University | EARLY_Phase 1 |
| Completed | Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis NCT03828643 | Universita di Verona | — |
| Completed | Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcri NCT03795402 | Janssen Research & Development, LLC | — |
| Completed | Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris NCT03806790 | LEO Pharma | Phase 3 |
| Terminated | A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects NCT03819218 | MC2 Therapeutics | Phase 2 |
| Recruiting | Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO) NCT04080635 | University Hospital, Ghent | N/A |
| Completed | This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group NCT03802344 | MC2 Therapeutics | Phase 3 |
| Unknown | The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis NCT03675542 | Aarhus University Hospital | Phase 1 |
| Completed | To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Foam, 0.005%/0.064%, in the Treatment of NCT03731091 | Glenmark Pharmaceuticals Ltd. India | Phase 3 |
| Completed | Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a NCT03669757 | LEO Pharma | Phase 1 |
| Completed | A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis NCT03614078 | PRCL Research Inc. | Phase 2 |
| Completed | Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin NCT03584360 | Centre Hospitalier Universitaire de Nice | Phase 2 |
| Completed | Informative Value of Determining the Level of NF-κB Translocation in Lymphocyte Populations in Children With P NCT04989296 | National Medical Research Center for Children's Health, Russian Federation | N/A |
| Terminated | Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris NCT03662685 | University of California, San Francisco | Phase 1 |
| Unknown | Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis NCT03469219 | Assiut University | — |
| Completed | Therapeutic Drug Monitoring of Guselkumab in Psoriasis Patients NCT04080648 | University Hospital, Ghent | Phase 4 |
| Completed | Body PSOriasis: Long-term Relapse CONTROL NCT03402828 | LEO Pharma | — |
| Unknown | Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis NCT03553433 | University of Zurich | Phase 4 |
| Unknown | Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis NCT03408756 | Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 4 |
| Completed | Therapeutic Drug Monitoring of Secukinumab in Psoriasis Patients. NCT04080661 | University Hospital, Ghent | Phase 4 |
| Completed | A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream NCT03462927 | MC2 Therapeutics | Phase 2 |
| Completed | Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese S NCT03442244 | LEO Pharma | Phase 1 |
| Unknown | Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Op NCT03307447 | Narrows Institute for Biomedical Research | Phase 4 |
| Completed | Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis NCT03348462 | Assiut University | Phase 4 |
| Completed | Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis NCT03359577 | Arctic Nutrition AS | N/A |
| Completed | Psoriatic Inflammation Markers Predictive of Response to Adalimumab NCT03389984 | Poitiers University Hospital | N/A |
| Completed | A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Aci NCT03331835 | LEO Pharma | Phase 4 |
| Completed | Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris NCT03322137 | Sienna Biopharmaceuticals | Phase 2 |
| Completed | A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream NCT03308799 | MC2 Therapeutics | Phase 3 |
| Completed | Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NCT03231124 | LEO Pharma | Phase 1 |
| Completed | LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris NCT02899962 | LEO Pharma | Phase 3 |
| Completed | PSOREAL - Managing PSOriasis in the REAL World NCT02935582 | LEO Pharma | — |
| Completed | A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis NCT03022617 | University of Alabama at Birmingham | Phase 4 |
| Completed | Vasoconstriction Trial With LEO 90100 Aerosol Foam NCT02973776 | LEO Pharma | Phase 1 |
| Completed | Safety and Efficacy of CD10367 in Psoriasis Vulgaris NCT03025282 | Galderma R&D | Phase 2 |
| Completed | Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis NCT03149900 | Diamant Thaci | — |
| Completed | LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris NCT02888236 | LEO Pharma | Phase 2 |
| Completed | A Phase 4 Clinical Study of Brodalumab NCT04183881 | Kyowa Kirin Co., Ltd. | Phase 4 |
| Terminated | A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects NCT02753218 | LEO Pharma | Phase 1 |
| Completed | TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment NCT02796053 | Theramab LLC | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to NCT02735187 | Philips Electronics Nederland BV | N/A |
| Completed | Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Pl NCT02387853 | LEO Pharma | Phase 2 |
| Completed | LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis NCT02668692 | LEO Pharma | Phase 3 |
| Completed | Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study NCT02636101 | LEO Pharma | — |
| Unknown | Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate NCT02715947 | Central South University | Phase 2 |
| Unknown | Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules NCT02715960 | Central South University | Phase 2 |
| Completed | An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A NCT02577185 | LEO Pharma | Phase 1 |
| Completed | Dermatopharmacokinetic Trial of LEO 80185 Gel NCT02605057 | LEO Pharma | Phase 1 |
| Completed | Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population NCT02533973 | LEO Pharma | Phase 4 |
| Completed | LEO 32731 - A Phase I Study in Healthy Subjects NCT02514694 | LEO Pharma | Phase 1 |
| Completed | Tissue Sodium in Patients With Psoriasis NCT04095130 | Charite University, Berlin, Germany | — |
| Completed | Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLA NCT03372811 | Psoriasis Research Institute of Guangzhou | Phase 2 |
| Unknown | Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris NCT02491658 | Affiliated Hospital to Academy of Military Medical Sciences | Phase 1 / Phase 2 |
| Completed | Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris NCT02310646 | LEO Pharma | Phase 3 |
| Completed | Phase 2, Open-label, Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy NCT02317627 | Kadmon Corporation, LLC | Phase 2 |
| Completed | A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis NCT02193815 | Pfizer | Phase 1 |
| Completed | LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis NCT02132936 | LEO Pharma | Phase 3 |
| Completed | Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis NCT02125279 | Galderma R&D | Phase 4 |
| Completed | LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects NCT02126371 | LEO Pharma | Phase 1 |
| Completed | A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis NCT02106195 | Kadmon Corporation, LLC | Phase 2 |
| Completed | Cardiovascular Risk Evaluation in Psoriasis Treated With Photochemotherapy NCT02990624 | Cairo University | N/A |
| Completed | A Phase 3 Clinical Study of KHK 4827 NCT02052609 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Su NCT02038569 | LEO Pharma | Phase 2 |
| Completed | Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgari NCT02004574 | Jooheung Lee | Phase 4 |
| Completed | Blue Light for Treating Psoriasis Vulgaris NCT02004847 | Philips Electronics Nederland BV | N/A |
| Completed | A Vasoconstriction Study With LEO 90100 NCT01946386 | LEO Pharma | Phase 1 |
| Completed | Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients NCT01936337 | Delenex Therapeutics AG | Phase 2 |
| Completed | Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100 NCT01935869 | LEO Pharma | Phase 1 |
| Completed | An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethason NCT01982552 | LEO Pharma | — |
| Completed | LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris NCT01866163 | LEO Pharma | Phase 3 |
| Completed | Tofacitinib Ointment For Chronic Plaque Psoriasis NCT01831466 | Pfizer | Phase 2 |
| Completed | An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone NCT01837576 | LEO Pharma | Phase 1 |
| Completed | Efficacy and Safety of Novel Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Pso NCT05488990 | Lipidor AB | Phase 1 / Phase 2 |
| Completed | Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris NCT01743118 | Circassia Limited | Phase 1 |
| Completed | Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP) NCT02902861 | Prof. Kristian Reich | Phase 3 |
| Unknown | Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psorias NCT01753245 | Juan Ruano | — |
| Completed | Mechanistic Study of Indigo Naturalis in Treating Psoriasis NCT02088281 | Chang Gung Memorial Hospital | Phase 2 |
| Unknown | The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic P NCT01651559 | Ahava Dead Sea Laboratories | — |
| Completed | Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment NCT01735864 | Chang Gung Memorial Hospital | N/A |
| Completed | Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formu NCT01707368 | LEO Pharma | — |
| Unknown | Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study NCT01702324 | Fortuderm Ltd. | Phase 1 / Phase 2 |
| Completed | The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects NCT01768013 | LEO Pharma | Phase 1 / Phase 2 |
| Completed | A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris NCT01607853 | LEO Pharma | Phase 2 |
| Completed | Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtens NCT01600222 | LEO Pharma | Phase 2 |
| Completed | LEO 90100 in the Treatment of Psoriasis Vulgaris NCT01536938 | LEO Pharma | Phase 2 |
| Completed | LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment NCT01536886 | LEO Pharma | Phase 2 |
| Completed | A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris NCT01580488 | LEO Pharma | Phase 1 |
| Completed | Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Ps NCT03069144 | Haus Bioceuticals | Phase 1 / Phase 2 |
| Completed | Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris NCT01465282 | Creabilis SA | Phase 2 |
| Completed | An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris NCT01466478 | LEO Pharma | Phase 1 |
| Completed | Incretin Effect in Patients With Psoriasis and Controls NCT06064084 | University Hospital, Gentofte, Copenhagen | — |
| Unknown | Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA2 NCT01443338 | Ministry of Health, China | Phase 4 |
| Completed | A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris NCT01347255 | LEO Pharma | Phase 2 |
| Completed | Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris NCT01320774 | LEO Pharma | — |
| Unknown | Efficacy of Vitamin D3 for the Treatment of Psoriatic Patients With Vitamin D Deficiency and Insufficiency NCT01339741 | Chulalongkorn University | N/A |
| Completed | A Psoriasis Plaque Test on LEO 27989 Ointment and Calcipotriol Plus LEO 27989 Ointment in Patients With Psoria NCT01297166 | LEO Pharma | Phase 1 |
| Completed | Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris NCT01229098 | LEO Pharma | Phase 2 |
| Completed | LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) NCT01188928 | LEO Pharma | Phase 3 |
| Completed | A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution f NCT01116895 | LEO Pharma | Phase 2 |
| Completed | A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Pso NCT01105286 | LEO Pharma | Phase 1 |
| Completed | A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Saf NCT01268527 | Eisai Limited | Phase 2 |
| Completed | Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis NCT01072383 | Biotest | Phase 2 |
| Completed | A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris NCT01043224 | LEO Pharma | Phase 1 |
| Completed | Comparison of Refined and Crude Indigo Naturalis Ointment in Treating Psoriasis NCT01022502 | Yin-ku Lin | Phase 2 |
| Completed | A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of NCT01007591 | LEO Pharma | Phase 3 |
| Completed | Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris NCT00817219 | LEO Pharma | Phase 2 |
| Terminated | Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis NCT00924950 | University of California, San Francisco | Phase 4 |
| Completed | A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products NCT00875277 | LEO Pharma | Phase 2 |
| Completed | A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris NCT00845481 | LEO Pharma | Phase 2 |
| Completed | LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjec NCT00833872 | LEO Pharma | Phase 1 |
| Completed | Use of Botulinum Toxin to Treat Psoriasis NCT00816517 | University of Minnesota | Phase 1 |
| Completed | Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris NCT00764751 | LEO Pharma | Phase 2 |
| Completed | Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in P NCT00704262 | LEO Pharma | Phase 2 |
| Completed | Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Fo NCT00691002 | LEO Pharma | Phase 3 |
| Completed | Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and NCT00670241 | LEO Pharma | Phase 3 |
| Completed | Safety and Efficacy of Combining nbUVB to Etanercept in Patients NCT00640393 | Innovaderm Research Inc. | Phase 4 |
| Unknown | Investigation of Antipsoriatic Effects of UVB-induced Synthesis of 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25( NCT00678756 | Technische Universität Dresden | Phase 2 |
| Completed | Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients NCT00640822 | LEO Pharma | Phase 3 |
| Completed | A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis NCT00593177 | Manhattan Pharmaceuticals | Phase 2 |
| Completed | Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris NCT00263718 | LEO Pharma | Phase 2 |
| Completed | Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgar NCT00248456 | LEO Pharma | Phase 4 |
| Unknown | Determination of Lymphocyte JAM-C Expression in Patients With Psoriasis Vulgaris NCT00365625 | Johann Wolfgang Goethe University Hospital | — |
| Completed | Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasi NCT00216892 | LEO Pharma | Phase 4 |
| Completed | Evaluation of Topical Antipsoriatics in the Psoriasis Plaque Test NCT00236171 | Technische Universität Dresden | N/A |
| Completed | Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psorias NCT00220025 | Mary Sullivan-Whalen | Phase 1 |
| Completed | Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis NCT00287547 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a NCT00277225 | Bristol-Myers Squibb | Phase 1 |
| Completed | Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris NCT00306878 | Bristol-Myers Squibb | Phase 1 |